December 27, 2013
Posted January 22, 2016
Abbott Labs agreed to pay $5.5M to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to use the company’s vascular products. The allegations were first raised in a qui tam lawsuit filed under the whistleblower provisions of the False Claims Act.DOJ
Tagged in: Anti-Kickback and Stark, FCA Federal, Pharma Fraud, Whistleblower Case,